Assenagon Asset Management S.A. Sells 13,513 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Assenagon Asset Management S.A. lessened its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 67.8% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 6,405 shares of the biopharmaceutical company's stock after selling 13,513 shares during the quarter. Assenagon Asset Management S.A.'s holdings in Alnylam Pharmaceuticals were worth $1,729,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of ALNY. Regeneron Pharmaceuticals Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $1,045,822,000. Norges Bank acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $577,941,000. Capital Research Global Investors lifted its stake in shares of Alnylam Pharmaceuticals by 32.9% during the 4th quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock worth $1,639,767,000 after buying an additional 1,724,610 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 39.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock worth $1,031,705,000 after buying an additional 1,245,195 shares during the last quarter. Finally, Marshall Wace LLP lifted its stake in shares of Alnylam Pharmaceuticals by 496.6% during the 4th quarter. Marshall Wace LLP now owns 378,649 shares of the biopharmaceutical company's stock worth $89,100,000 after buying an additional 315,182 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ALNY. Stifel Nicolaus lifted their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a "buy" rating in a research note on Monday, March 31st. Needham & Company LLC reiterated a "buy" rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 9th. HC Wainwright reiterated a "buy" rating and issued a $500.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 2nd. Wall Street Zen cut shares of Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, June 14th. Finally, Wells Fargo & Company lifted their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an "equal weight" rating in a research note on Friday, March 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $319.58.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 31,640 shares of the stock in a transaction on Friday, May 30th. The shares were sold at an average price of $304.39, for a total transaction of $9,630,899.60. Following the transaction, the chief executive officer now owns 48,948 shares of the company's stock, valued at approximately $14,899,281.72. This trade represents a 39.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Stock Down 0.8%

Shares of Alnylam Pharmaceuticals stock traded down $2.62 during trading on Friday, reaching $309.70. 1,336,724 shares of the company traded hands, compared to its average volume of 929,711. The company has a debt-to-equity ratio of 8.88, a current ratio of 3.04 and a quick ratio of 2.98. The company has a 50 day moving average price of $277.63 and a 200-day moving average price of $261.04. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $317.54. The firm has a market capitalization of $40.38 billion, a PE ratio of -148.18 and a beta of 0.22.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The firm had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The business's revenue was up 20.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.16) EPS. As a group, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.